UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000004480
Receipt No. R000005360
Scientific Title Clinical study to investigate the effects of mitiglinide add-on therapy with pioglitazone in patients with type 2 diabetes and cardiovascular disease.
Date of disclosure of the study information 2010/10/30
Last modified on 2012/11/02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Clinical study to investigate the effects of mitiglinide add-on therapy with pioglitazone in patients with type 2 diabetes and cardiovascular disease.
Acronym Vascular endothelial function by mitiglinide add-on therapy
Scientific Title Clinical study to investigate the effects of mitiglinide add-on therapy with pioglitazone in patients with type 2 diabetes and cardiovascular disease.
Scientific Title:Acronym Vascular endothelial function by mitiglinide add-on therapy
Region
Japan

Condition
Condition Patients withtype 2 diabetes and cardiovascular disease or atherosclerosis-prone.
Classification by specialty
Cardiology Endocrinology and Metabolism
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To investigate the anti-atherosclerotic effects of mitiglinide add-on therapy in patients with atherosclerosis-prone and type 2 diabetes, compared with pioglitazone alone.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Efficacy: Changes from baseline in vascular endothelial function
Safety: adverse event and laboratory tests
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Cross-over
Randomization Non-randomized
Randomization unit
Blinding Open -but assessor(s) are blinded
Control Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 dual treatment with mitiglinide (30 mg/day) and pioglitazone (15-30 mg/day) for 12 weeks
Interventions/Control_2 monotherapy with pioglitazone (15-30 mg/day) alone for 12 weeks
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria high-risk patients with cardiovascular disease with type 2 diabetes
1. pioglitazone usage (> 3 months)
2. HbA1c 6.5-8.0% (variance <0.5% in recent 2 months)
3. patients who agree the study dezine and protocol
Key exclusion criteria 1. acute coronary syndrome (< 3 weeks)
2. moderate to severe heart failure (BNP > 200 pg/mL)
3. SU usage in recent 3 months
4. insulin usage
5. severe diabetic retinopathy
6. mitiglinide usage
7. impossible to use mitiglinide or pioglitazone
8. impossible to evaluate precise effects of mitiglinide or pioglitazone
Target sample size 30

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Minako Yamaoka-Tojo
Organization Kitasato University School of Allied Health Sciences
Division name PT
Zip code
Address 1-15-1 Kitasato, Minami-ku, Sagamihara, Japan
TEL
Email

Public contact
Name of contact person
1st name
Middle name
Last name
Organization Kitasato University Hospital, Cardioangiology
Division name CRC center of Cardioangiology
Zip code
Address
TEL 042-778-8111
Homepage URL
Email

Sponsor
Institute Cardioangiology, Kitasato University School of Medicine
Institute
Department

Funding Source
Organization Cardioangiology, Kitasato University School of Medicine
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2010 Year 10 Month 30 Day

Related information
URL releasing protocol
Publication of results Published

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2010 Year 03 Month 30 Day
Date of IRB
Anticipated trial start date
2010 Year 04 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2010 Year 10 Month 30 Day
Last modified on
2012 Year 11 Month 02 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005360

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.